Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 05.10.2026 18 Ann Surg Oncol 3 Anticancer Res 1 Br J Cancer 1 Breast Cancer 2 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 6 Breast Cancer Res Treat 2 Breast J 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 10 Clin Breast Cancer 1 Clin Cancer Res 2 Eur J Cancer 1 Eur Radiol 5 J Clin Invest 1 J Clin Oncol 5 J Natl Cancer Inst 2 J Surg Oncol 1 Lancet Oncol 1 N Engl J Med 1 PLoS Comput Biol 1 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiol Imaging Cancer 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. FASANO GA, Mouabbi J, Johnson HM, Lin HY, et al
   Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma.
   Ann Surg Oncol. 2026;33:9609-9617.
   PubMed         Abstract available
   
   
2. DAOUD A, Li B, Lee H, Carr AA, et al
   Imaging Overestimates the Local Extent of Breast Tumor After Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2026;33:9752-9759.
   PubMed         Abstract available
   
   
3. ABELES E, Shui AM, Quirarte A, Barkin J, et al
   Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis.
   Ann Surg Oncol. 2026;33:9781-9790.
   PubMed         Abstract available
   
   
4. WILLIAMS AD, Lyons W, Taylor LB, Chang C, et al
   Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria.
   Ann Surg Oncol. 2026;33:9620-9629.
   PubMed         Abstract available
   
   
5. EUM JL, Hannigan CM, Smilen SH, Boolbol SK, et al
   Applicant Selection and Ranking in Breast Surgical Oncology Fellowships: A National Survey of Program Leadership.
   Ann Surg Oncol. 2026;33:9867-9874.
   PubMed         Abstract available
   
   
6. CAPUANO J, Silverstein MJ, Savalia N, Khan S, et al
   Extreme Oncoplasty: Avoiding Mastectomy and Expanding the Limits of Breast Conservation-A Comparative Study of 718 Patients.
   Ann Surg Oncol. 2026;33:9877-9883.
   PubMed         Abstract available
   
   
7. LEONARD SJ, Hoskin T, Siontis BL, Ahmed S, et al
   Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the Breast.
   Ann Surg Oncol. 2026;33:9834-9843.
   PubMed         Abstract available
   
   
8. SFARAD HK, Chen CB, Wang Y, Akcin M, et al
   Preoperative Overestimation of Disease Extent and Discordance-Driven Mastectomy: A Retrospective Review of 245 Cases.
   Ann Surg Oncol. 2026;33:9761-9768.
   PubMed         Abstract available
   
   
9. LUNT LG, Hoskin TL, Degnim AC, Olson CA, et al
   Time Interval Between Neoadjuvant Chemotherapy Completion and Mastectomy is Not Associated with 30-Day Complication Rate.
   Ann Surg Oncol. 2026;33:9803-9814.
   PubMed         Abstract available
   
   
10. JACKSON JE, Hartman S, Barkin J, Thaker H, et al
    Impact of Sentinel Node Omission in Early-Stage Breast Cancers on Adjuvant Therapy Decision-Making.
    Ann Surg Oncol. 2026;33:9828-9833.
    PubMed         Abstract available
    
    
11. LEE AJT, Cheung BHH, Suen DTK, Kwong A, et al
    Prospective Clinical Trial on Expanding the Eligibility Criteria for Targeted Axillary Dissection after Neoadjuvant Systemic Therapy in Breast Cancers with Advanced Nodal Disease.
    Ann Surg Oncol. 2026;33:9596-9603.
    PubMed         Abstract available
    
    
12. NUNEZ O, Rojas KE
    ASO Author Reflections: When Uncertainty Changes Surgery: Rethinking the Role of VUS in Breast Cancer Decision-Making.
    Ann Surg Oncol. 2026 Sep 26. doi: 10.1245/s10434-026-20664.
    PubMed        
    
    
13. CLARKE P, Pessoa EC, Coelho BA, de Araujo Brito Buttros D, et al
    ASO Visual Abstract: Cavity Margins Sample Shaving Evaluation as Part of Vacuum-Assisted Breast Biopsy: A Potential Approach to Predict Breast Cancer Excision.
    Ann Surg Oncol. 2026 Sep 28. doi: 10.1245/s10434-026-20551.
    PubMed        
    
    
14. TEITELBAUM A, Yono SS, Cheung WL, Springer K, et al
    Baseline Differences in Patient-Reported Quality of Life Across Breast Cancer Surgical Pathways.
    Ann Surg Oncol. 2026 Sep 30. doi: 10.1245/s10434-026-20617.
    PubMed         Abstract available
    
    
15. ELSAEDY EA, AlRammah T, Kawashima K, Ebos JML, et al
    ASO Author Reflections: Clinical Relevance of Aurora Kinase A (AURKA) Gene Expression in ER+/HER2- Breast Cancer.
    Ann Surg Oncol. 2026 Oct 1. doi: 10.1245/s10434-026-20698.
    PubMed        
    
    
16. VELAZQUEZ K, Jeng A, Roudakova K, Alberty-Oller JJ, et al
    Universal versus Guideline-Directed Germline Testing in Breast Cancer: Incremental Diagnostic Yield in a Predominantly Black Population.
    Ann Surg Oncol. 2026 Oct 1. doi: 10.1245/s10434-026-20637.
    PubMed         Abstract available
    
    
17. DE BRUIJN A, de Jonge C, Vriens BEP, van Kats MACE, et al
    ASO Visual Abstract: A Decade of Change: Systemic Treatment Patterns in Clinically Small HER2-Positive Node Negative Breast Cancer in the Netherlands: A Population-Based Study.
    Ann Surg Oncol. 2026 Oct 2. doi: 10.1245/s10434-026-20673.
    PubMed        
    
    
18. JOHNSON HM, Sun SX, Adelman DM, Chang EI, et al
    Timing of Surgical Axillary Staging and Impact on Technical Success of Immediate Lymphatic Reconstruction Following Axillary Lymph Node Dissection.
    Ann Surg Oncol. 2026;33:9731-9738.
    PubMed         Abstract available
    
    

    
    Anticancer Res

19. HARAGUCHI N, Yokoyama Y, Kubota Y, Kouda S, et al
    Hyperthermia Enhances the Effects of ICI by Increasing PD-L1 Expression Through Induction of CD8(+) Cell Infiltration.
    Anticancer Res. 2026;46:5399-5410.
    PubMed         Abstract available
    
    
20. FUSE Y, Fushimi A, Nameki A, Kawase K, et al
    Predicting Chemoresistance in HER2-low Breast Cancer: Histologic Grade, MRI Non-mass Enhancement, and Clinical T Stage.
    Anticancer Res. 2026;46:5689-5701.
    PubMed         Abstract available
    
    
21. CHANG WI, Jang BS, Chang JH, Kim K, et al
    Impact of Resection Margin Width on Local Control and Prognostic Factors in HER2-enriched and Triple-negative Breast Cancer in the Modern Systemic Treatment Era.
    Anticancer Res. 2026;46:5669-5678.
    PubMed         Abstract available
    
    

    
    Br J Cancer

22. LOPEZ JS, Im SA, Postel-Vinay S, Campone M, et al
    Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.
    Br J Cancer. 2026 Sep 30. doi: 10.1038/s41416-026-03601.
    PubMed         Abstract available
    
    

    
    Breast Cancer

23. BAS D, Agir G, Sonmez O, Ones E, et al
    Mindful eating as a supportive intervention for breast cancer survivors: a pilot randomized controlled trial.
    Breast Cancer. 2026 Sep 27. doi: 10.1007/s12282-026-01917.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

24. REZENDE AS, Gutman TCF, Cunha KS, Rodrigues FR, et al
    Investigation of the Residual Tumor Burden and Prognosis of Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:626207.
    PubMed         Abstract available
    
    
25. SHARAF B, Albatsh T, Khater S, Alrabie R, et al
    Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study.
    Breast Cancer (Dove Med Press). 2026;18:636314.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

26. KIESSLING S, Durackova J, Michler A, Geisen ABC, et al
    Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies.
    Breast Cancer Res. 2026;28:161.
    PubMed         Abstract available
    
    
27. NASRIN S, Oulhote Y, Grandjean P, Nielsen F, et al
    Serum perfluoroalkyl substances (PFASs) concentrations and associations with mammographic density in postmenopausal women.
    Breast Cancer Res. 2026;28:164.
    PubMed         Abstract available
    
    
28. FAN Y, Ouyang Q, Yin Y, Song L, et al
    Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.
    Breast Cancer Res. 2026;28:163.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

29. KOUMPRENTZIOTIS IA, Cawley A, Ewig E, Gerard AO, et al
    Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis.
    Breast Cancer Res Treat. 2026;219:24.
    PubMed         Abstract available
    
    
30. RAVAL P, Ding Q, Singh P, Alrohaibani A, et al
    HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2026;219:25.
    PubMed         Abstract available
    
    
31. AMIN LB, Kirkwood MK, Levit LA, Balogh EP, et al
    Geographic access to triple negative breast cancer clinical trials: are trials located near patients?
    Breast Cancer Res Treat. 2026;219:22.
    PubMed         Abstract available
    
    
32. PINHEIRO LC, Zeng C, Dorzhieva D, Joseph L, et al
    Implementation and evaluation of the Routine Assessment and Integration of Screening for Employment (RAISE) program in adults with metastatic breast cancer.
    Breast Cancer Res Treat. 2026;219:27.
    PubMed         Abstract available
    
    
33. MAHESWARAN S, Dedeoglu AS, Niemierko A, Abelman RO, et al
    Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability.
    Breast Cancer Res Treat. 2026;219:26.
    PubMed         Abstract available
    
    
34. OTTOSEN C, Kragelund E, Pedersen MA, Nguyen VQ, et al
    Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2026;219:23.
    PubMed         Abstract available
    
    

    
    Breast J

35. WEN M, Zhao Y, He C
    Lower-Cost Nonsurgical Primary Prevention Strategies for Women at High Risk of Breast Cancer: A Scoping Review.
    Breast J. 2026;2026:e1523594.
    PubMed         Abstract available
    
    
36. BELLAH SF
    Association of CYP3A5 Genetic Variants With Elevated Breast Cancer Risk: A Case-Control and In Silico Analysis.
    Breast J. 2026;2026:e9977157.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

37. SANGARAMOORTHY M, Goldberg D, Franke AA, DeRouen MC, et al
    Circulating 27-hydroxycholesterol, sex steroid hormones, and risk of mortality among postmenopausal females with breast cancer: The Multiethnic Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2026 Oct 2. doi: 10.1158/1055-9965.EPI-26-0180
    PubMed         Abstract available
    
    
38. WRIGHT SJ, Hilton J, Rogers G, Gray E, et al
    Implementing a Risk-Stratified National Breast Screening Programme in the United Kingdom: A Model-Based Cost-effectiveness Analysis.
    Cancer Epidemiol Biomarkers Prev. 2026;35:1752-1762.
    PubMed         Abstract available
    
    

    
    Cancer Res

39. PORRAS L, Carriere M, Gironne AS, Philippeau H, et al
    EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting.
    Cancer Res. 2026 Oct 2. doi: 10.1158/0008-5472.CAN-26-0801.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

40. SAMPATHKUMAR Y, Yu R, Sepahpour TY, Tokita HK, et al
    Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study.
    Clin Breast Cancer. 2026;26:10-17.
    PubMed         Abstract available
    
    
41. MA Y, Cheng L, Xu P, Wang Q, et al
    Prognostic Paradox of Breast Invasive Micropapillary Carcinoma.
    Clin Breast Cancer. 2026;26:1-9.
    PubMed         Abstract available
    
    
42. DOUGLAS A, Moore T, Hughes G, Bacani R, et al
    Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study.
    Clin Breast Cancer. 2026;26:9-16.
    PubMed         Abstract available
    
    
43. KIM YR, Jang MY, Chung JH, Kim YY, et al
    Clinical Outcomes and Chemoprevention in High-Risk Breast Lesions: A Comparison of Atypical Ductal Hyperplasia and Lobular Carcinoma In Situ.
    Clin Breast Cancer. 2026;26:169-174.
    PubMed         Abstract available
    
    
44. DING M, Zhang H, Wu Q, Xiang H, et al
    Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2- Breast Cancer: From Subtyping to Chemotherapy De-escalation.
    Clin Breast Cancer. 2026;26:162-168.
    PubMed         Abstract available
    
    
45. PAGANINI A, Ottosson J, Halle M, Gudbjornsdottir S, et al
    Characteristics of Massive Weight Loss Patients Having Implant-Based Breast Reconstruction After Mastectomy - A Case-Control Study.
    Clin Breast Cancer. 2026;26:156-161.
    PubMed         Abstract available
    
    
46. RICCIO M, Zingaretti N, Aquinati A, Ferraro AG, et al
    Oncoaesthetic Breast Reconstruction After Mastectomy Improves Patient Satisfaction and Aesthetic outcomes.
    Clin Breast Cancer. 2026;26:134-146.
    PubMed         Abstract available
    
    
47. MORA H, Cruz D, Goncalves D, Peleteiro B, et al
    Supine Magnetic Resonance Imaging in Breast-Conserving Surgery Planning: A Systematic Review of Margin and Re-excision Outcomes.
    Clin Breast Cancer. 2026;26:117-128.
    PubMed         Abstract available
    
    
48. DUAH-ASANTE K, Sivakanthan T, Oledajo I, Balogun A, et al
    Implications of Mobile Applications for Breast Surgery: A Systematic Review.
    Clin Breast Cancer. 2026;26:107-116.
    PubMed         Abstract available
    
    
49. UNTERKIRHERE O, Streller T, Jeller D, Logaritsch P, et al
    Ultra-Hypofractionated Whole-Breast Irradiation: Real-World Data From a Prospective Single-Institution Cohort.
    Clin Breast Cancer. 2026;26:97-106.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

50. NIRAVATH P, Uzair I, Sun K, Mai H, et al
    Correction: A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL).
    Clin Cancer Res. 2026;32:4504.
    PubMed        
    
    

    
    Eur J Cancer

51. LIUTTI VT, Wildiers H, Sonke GS, Neven P, et al
    Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?
    Eur J Cancer. 2026;248:117064.
    PubMed         Abstract available
    
    
52. DU Y, Meng Y, Liu X, Wang J, et al
    A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).
    Eur J Cancer. 2026;248:117063.
    PubMed         Abstract available
    
    

    
    Eur Radiol

53. RODRIGUEZ DE TRUJILLO CAMPO-CO, Romero Martin S, Rodriguez Alonso B, Font Ugalde P, et al
    Reply to the Letter to the Editor: Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy.
    Eur Radiol. 2026 Sep 28. doi: 10.1007/s00330-026-12929.
    PubMed        
    
    

    
    J Clin Invest

54. GUO C, Ellisen LW
    Antibody-drug conjugates in breast cancer: redefining targeted therapy.
    J Clin Invest. 2026;136:e207630.
    PubMed         Abstract available
    
    
55. FANUCCI KA, Bahnassy S, Roy AM, Sokolova A, et al
    Toward targeted therapeutics for lobular breast cancer.
    J Clin Invest. 2026;136:e207629.
    PubMed         Abstract available
    
    
56. WALMSLEY CS, Rodriguez A, Konstantinopoulos PA, Shapiro GI, et al
    Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
    J Clin Invest. 2026;136:e207632.
    PubMed         Abstract available
    
    
57. LYU Y, Talwar V, Yang Y, Kang SS, et al
    HIF-1-mediated PPME1 expression promotes breast cancer progression via AKT activation and beta-catenin recruitment.
    J Clin Invest. 2026;136:e205415.
    PubMed         Abstract available
    
    
58. KAY J, Dixon-Douglas JR, Harris MA, van Geelen CT, et al
    Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.
    J Clin Invest. 2026;136:e207634.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

59. BARRIO AV, Mautner S, Capko D, Choi DX, et al
    Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer.
    J Clin Oncol. 2026 Sep 29:JCO2601114. doi: 10.1200/JCO-26-01114.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

60. JOHN EM, Kwan ML, Koo J, Von Behren J, et al
    Obesity and survival of Asian American and White women with breast cancer.
    J Natl Cancer Inst. 2026 Oct 1:djag348. doi: 10.1093.
    PubMed         Abstract available
    
    
61. CARLIN D, Ott O, Sears DD, Ahles T, et al
    Exercise slows biological aging in breast cancer survivors: secondary analysis of a randomized trial.
    J Natl Cancer Inst. 2026 Sep 30:djag296. doi: 10.1093.
    PubMed         Abstract available
    
    
62. HARTMAN SJ, Shao LY, Zablocki RW, Natarajan L, et al
    Effectiveness of an exercise intervention on cognition in breast cancer survivors: a randomized controlled trial.
    J Natl Cancer Inst. 2026 Sep 30:djag295. doi: 10.1093.
    PubMed         Abstract available
    
    
63. RUIZ DE AZUA G, Licaj I, Ntobeng K, Havas J, et al
    Explaining educational differences in return to work after early breast cancer: a mediation analysis.
    J Natl Cancer Inst. 2026 Sep 29:djag350. doi: 10.1093.
    PubMed         Abstract available
    
    
64. VO JB, Mitra PR, Corley ME, Shiels MS, et al
    Trends in U.S. breast cancer mortality by estrogen receptor status.
    J Natl Cancer Inst. 2026 Sep 30:djag347. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

65. DEN J, Nelson N, Vaghjiani R, Suzanne Klimberg V, et al
    The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Peri- and Postmenopausal Breast Cancer Outcomes.
    J Surg Oncol. 2026 Sep 30. doi: 10.1002/jso.70411.
    PubMed         Abstract available
    
    
66. LOMBARDO GAG, Marchica P, Musmarra I, Martino B, et al
    Comparative Outcomes of Kiss Latissimus Dorsi Flap Versus Extended Thoracoabdominal Hatchet Flap for Large Chest Wall Reconstruction: A Retrospective Cohort Study.
    J Surg Oncol. 2026;134:739-747.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

67. SUN GY, Chen SY, Tang Y, Fang H, et al
    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.
    Lancet Oncol. 2026;27:1249-1259.
    PubMed         Abstract available
    
    

    
    N Engl J Med

68. MAYER EL, Tolaney SM, Martin M, Vidal GA, et al
    Giredestrant plus Everolimus in Advanced Breast Cancer.
    N Engl J Med. 2026;395:1285-1298.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

69. YANG C, Liao Y, Sheng Y, Jiao F, et al
    Integrating zero-inflation correction and transcriptional kinetics for single-cell transcriptomic analysis.
    PLoS Comput Biol. 2026;22:e1014779.
    PubMed         Abstract available
    
    

    
    PLoS One

70. XIAO Y, Fu J, Li J, Hu G, et al
    Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis.
    PLoS One. 2026;21:e0358540.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

71. BIAN X, Xu M, Li N, Sun C, et al
    Genome stability disrupted by the circRBM39(4,5,6)-RPA2 axis represses breast tumorigenesis.
    Proc Natl Acad Sci U S A. 2026;123:e2614237123.
    PubMed         Abstract available
    
    
72. LIANG Q, Zhu H, Huang BC, Lin TK, et al
    Development of A10P3C, an isoform-selective inhibitor of EGLN2, for targeting breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2613915123.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

73. GRIMM LJ, Wells V, Baker JA, Ghate SV, et al
    Causes of False-Negative Screening Digital Breast Tomosynthesis Examinations: A Multireader Study.
    Radiol Imaging Cancer. 2026;8:e260212.
    PubMed         Abstract available
    
    

    
    Radiology

74. MEEUWIS C, Dorrius MD
    Beyond Photon-counting CT: Multienergy CT across the Breast Cancer Pathway.
    Radiology. 2026;320:e262427.
    PubMed        
    
    

    
    Radiother Oncol

75. VISANI L, Becherini C, Kubeczko M, Caini S, et al
    Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2026 Sep 30:111800. doi: 10.1016/j.radonc.2026.111800.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum